Cowen analyst Phil Nadeau initiates coverage on PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) with a Outperform rating.The analyst comments "PhaseBio’s lead ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE